Our team

Claire DZIENGELEWSKI
Project Manager
Ph.D. in Molecular and Cellular Biology

Davy BAUDELET
Project Manager
Ph.D. in Medicinal Chemistry

Leila LAREDJ
Senior Project Manager, Team Leader
Ph.D. in Molecular Genetics

Reto ZWAHLEN
Project Manager
Ph.D. in Molecular Biology and Biochemistry

Marion LANDRY
Senior Project Manager, Quality Assurance Manager
Pharm.D., Ph.D. in Human and Nanomaterial Toxicology

Nathalie MULLER
Senior Project Manager, Deputy Quality Assurance Manager, Team Leader
Ph.D. in Cell Biology

Vincent DUBOIS
Managing Director, Head of Production
Ph.D. in Cell Biology and Biochemistry

Emmanuelle JORDI
Senior Project Manager, Head of Project Management, Team Leader
Ph.D. in Molecular and Cellular Neuroscience

Jonathan KEARSEY
Managing Director
Ph.D. in Molecular Biology

Julien MASSIOT
Project Manager
Ph.D. in Pharmaceutical Nanotechnology

Candice MARION
Senior Project Manager
Ph.D. in Neuroendocrinology

Julien ROSSIGNOL
Senior Project Manager
Ph.D. in Molecular Chemistry

Nathalie VALLE
Head of Quality Assurance
Pharm.D.

Stephanie DOWELL
Business Development Manager
Ph.D. in Molecular Pharmacology

Our history

Leads To Development (L2D) is a privately owned company that was formed in 2009 to create a high value service company that provides support for clients developing innovative drugs. We have now grown to an international team of drug development experts. Working from our offices in Paris, France, we provide hands-on scientific and regulatory expertise in all aspects of non-clinical drug development. Our services span all stages of the drug development process, but are often focussed on the earlier stages: from the discovery of a candidate new drug up to and including the first tests in humans.

The expertise that we have built over the last ten years allows our clients to increase the chance of the successfully developing their promising new drugs, whilst reducing the time taken to initiate the clinical studies.

Our mission is to provide our clients with non-clinical development solutions to enable their innovative products to enter clinical development successfully and rapidly, through the delivery of high quality, well planned and proactive operational and regulatory support